EUVIMEDEUVIMED entdecken
Open Access

Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies

Koki Nakashima, Yukihiro Umeda, Yoshiki Demura, Tomoaki Sonoda, Toshihiko Tada, Makiko Yamaguchi, Masaki Anzai, Maiko Kadowaki, Masahiro Oi, Chisato Honjo, Miho Mitsui, Yuko Waseda und 1 weitere

Oncology · 2024

DOI: 10.1159/000535994 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Koki Nakashima und 12 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Albumins. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Recent studies have suggested enhanced therapeutic effects of subsequent chemotherapy after immune checkpoint inhibitor (ICI) treatment, highlighting the importance of subsequent treatment selection. Nanoparticle albumin-bound paclitaxel (nab-PTX) is commonly used in subsequent chemotherapies; however, its efficacy as a subsequent treatment after ICI treatment has not been reported.

Methods

We retrospectively evaluated the efficacy and safety of nab-PTX using two prospective studies that we previously reported. The first study evaluated the efficacy and safety of nab-PTX as a second-line treatment after the failure of the first-line cytotoxic chemotherapy, excluding ICI (study 1; n = 32), and the other as a subsequent treatment after failure of ICI treatment, regardless of treatment line (study 2; n = 29).

Results

The objective response rate was significantly higher in study 2 {55.2% (95% confidence interval [CI]: 28.1–79.6)} than in study 1 (28.1% [95% CI: 13.7–46.7]) (p = 0.04). Although the disease control rate was slightly higher in study 2 (86.2% [95% CI: 65.9–97.0]) than in study 1 (71.9% [95% CI: 53.3–86.3]), there was no significant difference (p = 0.2). The median progression-free survival was significantly longer in study 2 than in study 1 (3.9 months [95% CI: 2.0–5.5] in study 1 vs. 5.6 months [95% CI: 3.0–12.8] in study 2; hazard ratio [HR]: 0.46 [95% CI: 0.27–0.81], p = 0.006). The median overall survival was slightly longer in study 2 despite the greater number of patients who received nab-PTX in late treatment line, but there was no significant difference between study 1 and study 2 (10.9 months [95% CI: 5.1–16.8] in study 1 vs. 11.9 months [95% CI: 7.6–24.8] in study 2; HR: 0.77 [95% CI: 0.46–1.31], p = 0.34). Safety profiles did not differ between the patients in studies 1 and 2.

Conclusion

Nab-PTX monotherapy may be an effective subsequent treatment option after ICI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsAlbuminsHumansFemaleMaleAgedMiddle AgedRetrospective StudiesProspective StudiesAlbumin-Bound PaclitaxelFollow-Up StudiesAged, 80 and overPaclitaxelAdultNanoparticlesTreatment Outcome

Stichwörter der Autor:innen

Immune checkpoint inhibitorNanoparticle albumin-bound paclitaxelNon-small cell lung cancerSubsequent treatment

Substanzen

Immune Checkpoint Inhibitors130-nm albumin-bound paclitaxelAlbuminsAlbumin-Bound PaclitaxelPaclitaxel

Autor:innen und Institutionen

  • Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
  • Department of Respiratory Medicine, Municipal Tsuruga Hospital, Fukui, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, Japan.

Zitieren

APA

Nakashima, K., Umeda, Y., Demura, Y., Sonoda, T., Tada, T., Yamaguchi, M., Anzai, M., Kadowaki, M., Oi, M., Honjo, C., Mitsui, M., Waseda, Y., & Ishizuka, T. (2024). Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies. Oncology. https://doi.org/10.1159/000535994

Vancouver

Nakashima K, Umeda Y, Demura Y, Sonoda T, Tada T, Yamaguchi M, et al. Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies. Oncology. 2024. doi:10.1159/000535994

BibTeX
@article{Nakashima2024,
  author = {Nakashima, Koki and Umeda, Yukihiro and Demura, Yoshiki and Sonoda, Tomoaki and Tada, Toshihiko and Yamaguchi, Makiko and Anzai, Masaki and Kadowaki, Maiko and Oi, Masahiro and Honjo, Chisato and Mitsui, Miho and Waseda, Yuko and Ishizuka, Tamotsu},
  title = {Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000535994}
}
Kostenlos starten →